Inspire® therapy is a mask-free solution for people with obstructive sleep apnea who have tried and struggled with CPAP. No mask. No hose. Just sleep.™
Bob Kronemyer (Contributor)
http://bit.ly/2Fd1JPu 根據今天在美國放射學會週年大會上發表的一項新研究,阻塞性睡眠呼吸暫停(Obstructive Sleep Apnea, OSA)和打鼻鼾可能導致女性心臟功能早期受損。阻塞性睡眠呼吸暫停是一種常見而暗藏危險的睡眠障礙,可增加心臟左右心室功能不全風險。 阻塞性睡眠呼吸暫停是最常見的睡眠障礙類型。它發生在喉部肌肉...
Inc.(NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (“OSA”), today announced an exclusive distributi...
Inspire Medical Systems, Inc. engages in the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea. It offers inspire therapy, which consists of a remote control and implantable components that includes pressure sensing lead, a neurostimulator, and a...
MINNEAPOLIS, June 09, 2023 (GLOBE NEWSWIRE) --Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obst...
The WVU Medicine Otolaryngology Sleep team has successfully completed its 100th Inspire implant procedure for treating obstructive sleep apnea (OSA). The Inspire device, which stimulates the hypoglossal nerve to keep airways open, offers a successful alternative to traditional CPAP the...
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provi...
is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea ("OSA"). Our proprietary Inspire system is the first and only United States ("U.S.") Food and Drug Administration ("FDA") European...
This quarterly report represents an earnings surprise of 328.57%. A quarter ago, it was expected that this maker of devices for treating obstructive sleep apnea would post a loss of $0.63 per share when it actually produced a loss of $0.34, delivering a surprise of 46.03%. ...